These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33157394)

  • 1. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.
    Teitel J; Sholzberg M; Iorio A
    Res Pract Thromb Haemost; 2021 Feb; 5(2):349-355. PubMed ID: 33733034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
    Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
    Megías-Vericat JE; Bonanad Boix S; Cid Haro AR; Haya Guaita S; Aguilar-Rodríguez M; Marqués-Miñana MR; Bosch P; Poveda Andrés JL
    Thromb Res; 2024 Jan; 233():135-137. PubMed ID: 38043392
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes.
    Croteau SE; Wheeler AP; Khan O; Haley KM; Borst AJ; Lattimore S; Yeung CHT; Iorio A
    Res Pract Thromb Haemost; 2020 Feb; 4(2):326-333. PubMed ID: 32110764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients.
    Hajducek DM; Chelle P; Iorio A; Iserman E; Edginton AN
    Haemophilia; 2024 Jul; 30(4):925-932. PubMed ID: 38738967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data.
    Chelle P; Hajducek D; Mahdi M; Young S; Iorio A; Silvertown J; Edginton A
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12599. PubMed ID: 34761154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
    Abbattista M; Ciavarella A; Noone D; Peyvandi F
    J Thromb Haemost; 2023 Mar; 21(3):546-552. PubMed ID: 36710195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
    Hua BL; Chelle P; Yeung C; Gu J; Zhao YQ; Iorio A
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):673-677. PubMed ID: 31495135
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.
    Chen Z; Huang K; Li G; Zhen Y; Wu X; Di A; Liu G; Li Z; Alfonso I; Wu R
    Pediatr Investig; 2021 Mar; 5(1):38-45. PubMed ID: 33778426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
    Morfini M; Gherardini S
    Ther Adv Hematol; 2018 Jun; 9(6):149-162. PubMed ID: 29899890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review.
    Ay C; Napolitano M; Hassoun A; Tomic R; Martin C; Seifert W; Pinachyan K; Oldenburg J
    Haemophilia; 2024 May; 30(3):577-588. PubMed ID: 38549463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
    Oldenburg J; Benson G; Chowdary P; Halimeh S; Matsushita T; Nørland A; Wahid MN; Nemes L
    Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding management: rFVIIIFc in hemophilia A and liver transplantation.
    Grottke O; Rieg A; Ulmer F; Hein M
    Anaesthesiologie; 2023 Dec; 72(12):883-886. PubMed ID: 37563315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project.
    Ucero-Lozano R; Pérez-Llanes R; Cuesta-Barriuso R; Donoso-Úbeda E
    Pharmaceuticals (Basel); 2024 Jun; 17(7):. PubMed ID: 39065686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.
    Goedhart TMHJ; Bukkems LH; Zwagemaker AF; Coppens M; Fijnvandraat K; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
    Res Pract Thromb Haemost; 2024 Mar; 8(3):102397. PubMed ID: 38689619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform.
    Chelle P; Hajducek D; Thibaudeau K; Hobson N; Iorio A; Shapiro A; Edginton A
    Haemophilia; 2024 Jul; 30(4):988-997. PubMed ID: 38698539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement.
    Ozelo MC; Antunes SV; Villaca PR; Oliveira LC; Pinto IS; Lorenzato CS; Prezotti ANL; Picoli RM
    Hematol Transfus Cell Ther; 2024; 46(1):36-41. PubMed ID: 36604239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PK-tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital.
    Li P; Chen Z; Cheng X; Wang Y; Zhang N; Zhen Y; Wu X; Wu R
    Pediatr Investig; 2019 Mar; 3(1):45-49. PubMed ID: 32851288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
    Fukutake K; Togo K; Xu L; Markson LE; Alvir JMJ; Winburn I; Karumori T
    J Blood Med; 2023; 14():649-661. PubMed ID: 38143791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.